---
title: "Stage distribution and stage-specific survival drive lung cancer survival gaps for Māori in Aotear"
id: "pubmed-43056629"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-43056629"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/43056629/"
doi: "10.26635/6965.7656"
published_at: "2026-11-20T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Stage distribution and stage-specific survival drive lung cancer survival gaps for Māori in Aotear
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-43056629
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/43056629/)
- **DOI:** [10.26635/6965.7656](https://doi.org/10.26635%2F6965.7656)
- **Published At:** 2026-11-20T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- The study used national cancer registry records to compare **Māori** and European populations with **lung cancer**, diagnosed 2015–2024, with mortality follow-up to December 2025. - Investigators modelled survival using sex-specific Cox regression that included age, year of diagnosis, ethnicity, SEER summary stage, and an ethnicity-by-stage interaction. - Survival probabilities were estimated at 1, 3 and 5 years; the abstract reports 5-year survival only for key comparisons. - Observed 5-year survival was lower for Māori than Europeans: males 11.3% (95% CI 9.4–13.7) vs 16.8% (95% CI 15.2–18.7); females 17.1% (95% CI 15.0–19.5) vs 24.2% (95% CI 22.5–26.2). - Scenario standardisation was applied to Māori estimates in three ways: standardise stage distribution to Europeans; standardise stage-specific survival to Europeans; and standardise both simultaneously. - Standardising stage distribution alone increased estimated 5-year survival for Māori males to 13.5% (95% CI 11.4–16.2) and females to 20.2% (95% CI 17.9–22.9). - Standardising stage-specific survival produced larger increases: males to 17.2% (95% CI 15.4–19.3) and females to 23.4% (95% CI 21.5–25.6). - Applying both standardisations yielded the highest 5-year estimates for Māori: males 19.5% (95% CI 17.7–21.7) and females 26.6% (95% CI 24.7–28.8). - Authors concluded that differences in both **stage distribution** and stage-specific survival contributed to inequities in lung cancer survival, with stage-specific survival having the larger single effect. - The abstract does not report sample sizes, detailed stage breakdowns, cause-specific survival vs overall survival distinction, or additional covariates beyond those listed; those methodological details were not reported in the source abstract.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/43056629/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43056629%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/43056629/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/43056629/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/43056629/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/43056629/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/43056629/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/43056629/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43056629%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43056629%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/43056629/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/43056629/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/43056629/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/43056629/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/43056629/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/43056629/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/43056629/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/43056629/#conflict-of-interest) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/43056629/#mesh-terms) Title & authors Abstract Conflict of interest statement MeSH terms N Z Med J Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22N+Z+Med+J%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22N+Z+Med+J%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43056629/) . 2026 Nov 20;139(1646):75-87. doi: 10.26635/6965.7656. # Scenario-based analysis of stage distribution and stage-specific survival among Māori diagnosed with lung cancer in Aotearoa New Zealand [Michael Walsh](https://pubmed.ncbi.nlm.nih.gov/?term=Walsh+M&cauthor_id=43056629)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/43056629/#full-view-affiliation-1 "Epidemiologist, Planning, Funding and Outcomes, Health New Zealand - Te Whatu Ora."), [Karen Bartholomew](https://pubmed.ncbi.nlm.nih.gov/?term=Bartholomew+K&cauthor_id=43056629)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43056629/#full-view-affiliation-2 "Director of Health Gain Development, Planning, Funding and Outcomes, Health New Zealand - Te Whatu Ora."), [Jason Gurney](https://pubmed.ncbi.nlm.nih.gov/?term=Gurney+J&cauthor_id=43056629)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/43056629/#full-view-affiliation-3 "Professor, Department of Public Health, University of Otago."), [Kate Parker](https://pubmed.ncbi.nlm.nih.gov/?term=Parker+K&cauthor_id=43056629)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/43056629/#full-view-affiliation-4 "Programme Manager, Planning, Funding and Outcomes, Health New Zealand - Te Whatu Ora."), [Dale Bramley](https://pubmed.ncbi.nlm.nih.gov/?term=Bramley+D&cauthor_id=43056629)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/43056629/#full-view-affiliation-5 "Public Health Physician, Health New Zealand - Te Whatu Ora."), [Sue Crengle](https://pubmed.ncbi.nlm.nih.gov/?term=Crengle+S&cauthor_id=43056629)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/43056629/#full-view-affiliation-6 "Professor, Ngai Tahu Māori Health Research Unit, University of Otago.") Affiliations Expand ### Affiliations * 1 Epidemiologist, Planning, Funding and Outcomes, Health New Zealand - Te Whatu Ora. * 2 Director of Health Gain Development, Planning, Funding and Outcomes, Health New Zealand - Te Whatu Ora. * 3 Professor, Department of Public Health, University of Otago. * 4 Programme Manager, Planning, Funding and Outcomes, Health New Zealand - Te Whatu Ora. * 5 Public Health Physician, Health New Zealand - Te Whatu Ora. * 6 Professor, Ngai Tahu Māori Health Research Unit, University of Otago. * PMID: **43056629** * DOI: [ 10.26635/6965.7656 ](https://doi.org/10.26635/6965.7656) Item in Clipboard # Scenario-based analysis of stage distribution and stage-specific survival among Māori diagnosed with lung cancer in Aotearoa New Zealand Michael Walsh et al. N Z Med J. 2026. Show details Display options Display options Format Abstract PubMed PMID N Z Med J Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22N+Z+Med+J%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22N+Z+Med+J%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43056629/) . 2026 Nov 20;139(1646):75-87. doi: 10.26635/6965.7656. ### Authors [Michael Walsh](https://pubmed.ncbi.nlm.nih.gov/?term=Walsh+M&cauthor_id=43056629)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/43056629/#short-view-affiliation-1 "Epidemiologist, Planning, Funding and Outcomes, Health New Zealand - Te Whatu Ora."), [Karen Bartholomew](https://pubmed.ncbi.nlm.nih.gov/?term=Bartholomew+K&cauthor_id=43056629)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43056629/#short-view-affiliation-2 "Director of Health Gain Development, Planning, Funding and Outcomes, Health New Zealand - Te Whatu Ora."), [Jason Gurney](https://pubmed.ncbi.nlm.nih.gov/?term=Gurney+J&cauthor_id=43056629)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/43056629/#short-view-affiliation-3 "Professor, Department of Public Health, University of Otago."), [Kate Parker](https://pubmed.ncbi.nlm.nih.gov/?term=Parker+K&cauthor_id=43056629)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/43056629/#short-view-affiliation-4 "Programme Manager, Planning, Funding and Outcomes, Health New Zealand - Te Whatu Ora."), [Dale Bramley](https://pubmed.ncbi.nlm.nih.gov/?term=Bramley+D&cauthor_id=43056629)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/43056629/#short-view-affiliation-5 "Public Health Physician, Health New Zealand - Te Whatu Ora."), [Sue Crengle](https://pubmed.ncbi.nlm.nih.gov/?term=Crengle+S&cauthor_id=43056629)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/43056629/#short-view-affiliation-6 "Professor, Ngai Tahu Māori Health Research Unit, University of Otago.") ### Affiliations * 1 Epidemiologist, Planning, Funding and Outcomes, Health New Zealand - Te Whatu Ora. * 2 Director of Health Gain Development, Planning, Funding and Outcomes, Health New Zealand - Te Whatu Ora. * 3 Professor, Department of Public Health, University of Otago. * 4 Programme Manager, Planning, Funding and Outcomes, Health New Zealand - Te Whatu Ora. * 5 Public Health Physician, Health New Zealand - Te Whatu Ora. * 6 Professor, Ngai Tahu Māori Health Research Unit, University of Otago. * PMID: **43056629** * DOI: [ 10.26635/6965.7656 ](https://doi.org/10.26635/6965.7656) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract **Introduction:** Lung cancer survival in Aotearoa New Zealand differs between Māori and European populations. This study used scenario-based standardisation to compare survival when Māori estimates were standardised to the European stage distribution, stage-specific survival or both. The scenarios aimed to assess which of these differences was associated with the larger change in estimated survival. **Methods:** National cancer registry data were used to identify all primary lung cancers for Māori and European populations diagnosed between 2015 and 2024, with mortality follow-up to December 2025. Survival was modelled using sex-specific Cox regression, including age at diagnosis and diagnosis year, ethnicity, Surveillance, Epidemiology, and End Results (SEER) summary stage, and an ethnicity-by-stage interaction. Survival probabilities at 1, 3 and 5 years were estimated. Scenarios were constructed for Māori in which stage distribution, stage-specific survival or both were standardised to those of Europeans. **Results:** Five-year survival was lower for Māori than for Europeans among males (11.3%, 95% confidence interval [CI] 9.4-13.7 vs 16.8%, 95% CI 15.2-18.7) and females (17.1%, 95% CI 15.0-19.5 vs 24.2%, 95% CI 22.5-26.2). Standardising stage distribution increased estimated 5-year survival to 13.5% (95% CI 11.4-16.2) for Māori males and 20.2% (95% CI 17.9-22.9) for Māori females. Standardising stage-specific survival produced larger increases, to 17.2% (95% CI 15.4-19.3) and 23.4% (95% CI 21.5-25.6), respectively. Estimates were highest when both were standardised, at 19.5% (95% CI 17.7-21.7) and 26.6% (95% CI 24.7-28.8). **Conclusions:** Differences in both stage distribution and stage-specific survival were associated with lung cancer survival inequities. Standardising stage-specific survival produced a larger change than standardising stage distribution alone. © PMA. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement DB is a chief executive officer for Health New Zealand – Te Whatu Ora. ## MeSH terms * Adult Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Adult%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Adult) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43056629/) * Aged Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Aged%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Aged) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43056629/) * Aged, 80 and over Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Aged%2C+80+and+over%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Aged%2C+80+and+over) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43056629/) * Female Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Female%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Female) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43056629/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43056629/) * Lung Neoplasms* / ethnology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Lung+Neoplasms%2Fethnology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Lung+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43056629/) * Lung Neoplasms* / mortality Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Lung+Neoplasms%2Fmortality%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Lung+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43056629/) * Lung Neoplasms* / pathology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Lung+Neoplasms%2Fpathology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Lung+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43056629/) * Male Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Male%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Male) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43056629/) * Maori People Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Maori+People%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Maori+People) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43056629/) * Middle Aged Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Middle+Aged%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Middle+Aged) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43056629/) * Neoplasm Staging Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Neoplasm+Staging%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Neoplasm+Staging) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43056629/) * New Zealand / epidemiology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22New+Zealand%2Fepidemiology%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=New+Zealand) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43056629/) * Registries Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Registries%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Registries) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43056629/) * Survival Analysis Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Survival+Analysis%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Survival+Analysis) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43056629/) * Survival Rate Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Survival+Rate%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Survival+Rate) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43056629/) * White People / statistics & numerical data Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22White+People%2Fstatistics+and+numerical+data%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=White+People) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43056629/) [x] Cite Copy Download .nbib .nbib Format: AMA APA MLA NLM **Send To** * [Clipboard](https://pubmed.ncbi.nlm.nih.gov/43056629/) * [Email](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43056629%2F%23open-email-panel) * [Save](https://pubmed.ncbi.nlm.nih.gov/43056629/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43056629%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43056629%2F%23open-collections-panel) * [Citation Manager](https://pubmed.ncbi.nlm.nih.gov/43056629/) [x] NCBI Literature Resources [MeSH](https://www.ncbi.nlm.nih.gov/mesh/) [PMC](https://www.ncbi.nlm.nih.gov/pmc/) [Bookshelf](https://www.ncbi.nlm.nih.gov/books) [Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited. Follow NCBI [ Twitter ](https://twitter.com/ncbi) [ Facebook ](https://www.facebook.com/ncbi.nlm) [ LinkedIn ](https://www.linkedin.com/company/ncbinlm) [ GitHub ](https://github.com/ncbi) [ ](https://ncbiinsights.ncbi.nlm.nih.gov/) [Connect with NLM](https://www.nlm.nih.gov/socialmedia/index.html) * [ Twitter ](https://twitter.com/NLM_NIH) * [ SM-Facebook ](https://www.facebook.com/nationallibraryofmedicine) * [ SM-Youtube ](https://www.youtube.com/user/NLMNIH) National Library of Medicine [8600 Rockville Pike Bethesda, MD 20894](https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323) [Web Policies](https://www.nlm.nih.gov/web_policies.html) [FOIA](https://www.nih.gov/institutes-nih/nih-office-director/off
## Related Clinical Research

- [Early STAT+ Results for Alterome’s KRAS Inhibitor in Pancreatic, Lung, and Colorectal Cancer](https://medichelpline.com/clinical-feed/stat-news-1-stat-early-results-for-alterome-s-kras-drug-for-pancreas-lung-and-colon-cancer.md)
- [COMMD1 in Cancer: Dual Roles, Mechanisms, and Translational Targets](https://medichelpline.com/clinical-feed/pubmed-43059391.md) (DOI: 10.3892/or.2026.9224)
- [LCatlas: Point-of-Care Prediction Tool for Immunotherapy Response in NSCLC](https://medichelpline.com/clinical-feed/medrxiv-19-lcatlas-a-point-of-care-tool-for-predicting-immunotherapy-outcomes-in-non-small.md)
- [FDA leadership void after Overton withdrawal; FDA rejects lung cancer drug and STAT ranks China’s](https://medichelpline.com/clinical-feed/stat-news-1-fda-s-search-for-a-new-leader-and-china-s-largest-drugmakers.md)
- [Access to FDG PET-CT for Lung Cancer in Te Manawa Taki Midland Region, New Zealand](https://medichelpline.com/clinical-feed/pubmed-43056627.md) (DOI: 10.26635/6965.7523)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.